<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

WEBINAR: Shifting the Paradigm of Cancer Treatment: How Can Optical Imaging Help?

Friday October 30th, 9am ET/3pm BST; 1pm ET/7pm BST

Join Dr Yinfei Yin to explore the benefits of optical imaging in preclinical oncology research with an emphasis on immunotherapy development. Learn how imaging improves the predictive power of preclinical studies, and allows a more efficient and cost-effective translation into the clinic. Key new imaging models for evaluating novel anticancer agents will also be discussed.

NEW WHITE PAPER: Learn When and How to Use Tumor Organoids in Oncology Drug Discovery

Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms.

ON DEMAND WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research

Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies.

Keeping Your Projects Moving During the

COVID-19 Pandemic

Read the update from Dr. Jean-Pierre Wery, CEO on how we're balancing our operations while keeping our staff and facilities safe. Find out more about our current global capacity - with all China sites fully operational, and a Proxy SD system for EU/US affected areas

NEW PUBLICATION: Genomic Analysis of Clinical Chinese ccRCC Samples to Guide Patient Stratification

Explore whole-transcriptomic analysis of tumor and matched normal tissues from Chinese ccRCC patients, to investigate differences in expression profiles across Chinese and Caucasian populations. Discover how genomic analysis of clinical samples has the potential to guide patient stratification.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.


Models of Obesity


CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More


Oncology Databases


Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More


Diabetes Models


Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

October 21, 2020

Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist

Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our new Utrecht site.

Read More

October 21, 2020

Meet the CrownBio Team: Dr Marrit Putker, Organoid Research Scientist

Meet the newest member of CrownBio’s organoid team, Marrit Putker, heading up research at our...

Read More

October 14, 2020

Evaluating Immunotherapy Mechanism of Action with Immune Cell Lineage-Specific DTR Models

Explore how transgenic diphtheria toxin receptor (DTR) preclinical models are used to better...

Read More

October 2, 2020

Next Generation Syngeneic Models: Top 14 Questions

Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most...

Read More

September 22, 2020

T Cell Dysfunction Assays for In Vitro Screening of Immunomodulatory Drug Candidates

Review the latest advances in the recall antigen assay, to provide an optimized system for...

Read More

September 17, 2020

HUB Technology: The Only Tumor Organoid Platform Available for Oncology Drug Discovery

Explore why adult stem cell (ASC)-derived HUB technology provides the only tumor organoid...

Read More

Upcoming Events

October 24-25, 2020

32nd EORTC-NCI-AACR Symposium


November 9-14, 2020

SITC 2020